Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28342102 | 1.00 | KDM4E (0.48) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL15507141 | 1.00 | KDM4E (0.48) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL4164966 | 1.00 | KDM4E (0.48) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL4164968 | 1.00 | KDM4E (0.48) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL25465736 | 0.88 | KDM4E (0.47) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL30661567 | 0.88 | KDM4E (0.47) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL19813102 | 0.88 | KDM4E (0.47) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL17966350 | 0.88 | KDM4E (0.47) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL17966352 | 0.88 | KDM4E (0.47) | KDM4EPKMGPR119NPC1ALDH1A1 | |
| SCHEMBL17966353 | 0.88 | KDM4E (0.47) | KDM4EPKMGPR119NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612302-B | Pyrazolo [1,5-a ] pyrimidine derivatives as kinase JAK inhibitors | 赛隆制药股份公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-110612302-A | Pyrazolo [1,5-a ] pyrimidine derivatives as kinase JAK inhibitors | 赛隆制药股份公司 | 2019-12-24 | — | — | CN | disclosed |
| EP-2892899-B1 | IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2892899-B1 | IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2686321-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-9428511-B2 | Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150210703-A1 | IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-30 | — | — | US | disclosed |
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011800-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | KDM4E 1141/4885PKM 957/4885GPR119 3922/4885 |
| US-20150210703-A1 | IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | KDM4E 1157/4885PKM 1536/4885GPR119 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.